Advanced search
Start date

Integrative epigenomic analysis of gliomas: defining regulatory regions associated with stemness and with the hypermethylator phenotype of IDH1/2 mutant tumors

Grant number: 18/00583-0
Support type:Research Grants - Young Investigators Grants
Duration: September 01, 2019 - August 31, 2023
Field of knowledge:Health Sciences - Medicine - Medical Clinics
Principal Investigator:Tathiane Maistro Malta Pereira
Grantee:Tathiane Maistro Malta Pereira
Home Institution: Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
Assoc. researchers:Ana Valeria Castro ; Fabíola Attié de Castro ; Houtan Noushmehr ; Sergio Akira Uyemura
Associated scholarship(s):20/09046-7 - Mapping stemness epigenomic signatures in gliomas, BP.IC
20/05492-2 - Identification of regulatory regions associated with mutation in the IDH1/2 genes in different tumor types, BP.MS
19/14928-1 - Integrative epigenomic analysis of gliomas - defining regulatory regions associated with stemness and with the hypermethylator phenotype of IDH1/2 mutant tumors, BP.JP


Adult malignant Gliomas are heterogeneous brain tumors characterized by recurrence and progression with variable patterns. Although some progress has been seen in the past years, Glioma field faces suboptimal disease classification, which may impact patient management and hinder the correct treatment. Mutation in the IDH genes, the hypermethylator G-CIMP phenotype and codeletion of chromosome arms 1p/19q are associated with subtypes of Gliomas and improve their classification. Notably, increasing evidence suggests that aberrant DNA methylation play a role in the development and/or progression of Gliomas. In glioblastomas, it is appreciated that differentiation status impacts tumor cell properties and that stem-like cells likely drive tumor progression and therapeutic resistance. We aim to perform a comprehensive and integrated epigenomic analysis to define the regulatory regions associated with stemness in Gliomas and with the hypermethylator phenotype of IDH1/2 mutation in Gliomas and across different tumor types. Our findings may provide: 1) elucidation of the mechanisms of tumorigenesis and tumor progression; 2) potential mechanisms related to the genome-wide DNA methylation and metabolism dysregulation in IDH1/2 mutant tumors; and 3) potential translational outcomes, such as identification of biomarkers that predict for progression and drug resistance, novel targets for drug development, refinement of existing molecular tumor classification allowing a better stratification for tailored treatment. Finally, this proposal will establish the innovative area of cancer epigenomics at FCFRP, which will allow important collaboration and contribute to expanding the research actions at FCFRP. (AU)